1,969
Views
22
CrossRef citations to date
0
Altmetric
Report

Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display

, , , , , , , , , , & show all
Pages 341-348 | Published online: 26 Apr 2012

References

  • Reichert JM. Metrics for antibody therapeutics development. MAbs 2010; 2:695 - 700; http://dx.doi.org/10.4161/mabs.2.6.13603; PMID: 20930555
  • Lerner RA. Manufacturing immunity to disease in a test tube: the magic bullet realized. Angew Chem Int Ed Engl 2006; 45:8106 - 25; http://dx.doi.org/10.1002/anie.200603381; PMID: 17120282
  • Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A 2000; 97:10701 - 5; http://dx.doi.org/10.1073/pnas.170297297; PMID: 10984501
  • Steidl S, Ratsch O, Brocks B, Dürr M, Thomassen-Wolf E. In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol Immunol 2008; 46:135 - 44; http://dx.doi.org/10.1016/j.molimm.2008.07.013; PMID: 18722015
  • Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23:1105 - 16; http://dx.doi.org/10.1038/nbt1126; PMID: 16151404
  • Kay BK, Adey NB, He YS, Manfredi JP, Mataragnon AH, Fowlkes DM. An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets. Gene 1993; 128:59 - 65; http://dx.doi.org/10.1016/0378-1119(93)90153-T; PMID: 8508960
  • Clackson T, Wells JA. In vitro selection from protein and peptide libraries. Trends Biotechnol 1994; 12:173 - 84; http://dx.doi.org/10.1016/0167-7799(94)90079-5; PMID: 7764900
  • Derda R, Tang SK, Li SC, Ng S, Matochko W, Jafari MR. Diversity of phage-displayed libraries of peptides during panning and amplification. Molecules 2011; 16:1776 - 803; http://dx.doi.org/10.3390/molecules16021776; PMID: 21339712
  • Krebber A, Burmester J, Plückthun A. Inclusion of an upstream transcriptional terminator in phage display vectors abolishes background expression of toxic fusions with coat protein g3p. Gene 1996; 178:71 - 4; http://dx.doi.org/10.1016/0378-1119(96)00337-X; PMID: 8921894
  • Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov 2003; 2:693 - 4; http://dx.doi.org/10.1038/nrd1182; PMID: 12953696
  • Osbourn J, Groves M, Vaughan T. From rodent reagents to human therapeutics using antibody guided selection. Methods 2005; 36:61 - 8; http://dx.doi.org/10.1016/j.ymeth.2005.01.006; PMID: 15848075
  • Rajpal A, Beyaz N, Haber L, Cappuccilli G, Yee H, Bhatt RR, et al. A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci U S A 2005; 102:8466 - 71; http://dx.doi.org/10.1073/pnas.0503543102; PMID: 15939870
  • Salfeld JG, Allen DJ, Hoogenboom HR, Kaymakcalan Z, Labkovsky B, Mankovich JA, et al. Human antibodies that bind human TNFα. U.S. Patent 2003; 6,090,382.
  • Kabat EA, Wu TT, Reid-Miller M, Perry H, Gottesman K. Sequences of Proteins of Immunological Interest, US Govt. Printing Off. 1987; Fourth Edition: 165-492.
  • Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927 - 48; http://dx.doi.org/10.1006/jmbi.1997.1354; PMID: 9367782
  • Web Antibody Modeling. . http://antibody.bath.ac.uk
  • MacCallum RM, Martin AC, Thornton JM. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 1996; 262:732 - 45; http://dx.doi.org/10.1006/jmbi.1996.0548; PMID: 8876650
  • Jansson B, Uhlén M, Nygren PA. All individual domains of staphylococcal protein A show Fab binding. FEMS Immunol Med Microbiol 1998; 20:69 - 78; http://dx.doi.org/10.1016/S0928-8244(97)00108-9; PMID: 9514577
  • Wark KL, Hudson PJ. Latest technologies for the enhancement of antibody affinity. Adv Drug Deliv Rev 2006; 58:657 - 70; http://dx.doi.org/10.1016/j.addr.2006.01.025; PMID: 16828920
  • Foote J, Eisen HN. Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci U S A 1995; 92:1254 - 6; http://dx.doi.org/10.1073/pnas.92.5.1254; PMID: 7877964
  • Jermutus L, Honegger A, Schwesinger F, Hanes J, Plückthun A. Tailoring in vitro evolution for protein affinity or stability. Proc Natl Acad Sci U S A 2001; 98:75 - 80; http://dx.doi.org/10.1073/pnas.011311398; PMID: 11134506
  • Hanes J, Plückthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci U S A 1997; 94:4937 - 42; http://dx.doi.org/10.1073/pnas.94.10.4937; PMID: 9144168
  • Wu H. Simultaneous humanization and affinity optimization of monoclonal antibodies. Methods Mol Biol 2003; 207:197 - 212; PMID: 12412476
  • Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 2001; 299:119 - 29; http://dx.doi.org/10.1006/abio.2001.5380; PMID: 11730333
  • Kwong KY, Rader C. E.coli Expression and Purification of Fab Antibody Fragments. Curr Protoc Protein Sci. 2009; 6: Unit 6.10.
  • Krippner-Heidenreich A, Tübing F, Bryde S, Willi S, Zimmermann G, Scheurich P. Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction. J Biol Chem 2002; 277:44155 - 63; http://dx.doi.org/10.1074/jbc.M207399200; PMID: 12215450